Maximal NCE Tumor Resection Impacts Glioblastoma Survival

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of non–contrast enhanced (NCE) tumor as well as contrast-enhanced (CE) tumor is associated with increased survival regardless of tumor subtype, according to a study recently published in JAMA Oncology.Glioblastoma subtypes are known to impact disease outcome: while the 91% of patients with glioblastoma whose tumors display isocitrate dehydrogenase gene 1 or 2­­ (IDH) wild-type mutations have a median survival of...
Continue reading

Biomarkers in Liquid Biopsies Detect Glioblastoma Tumors

Researchers have identified glioblastoma biomarkers in extracellular vesicles that could enable a liquid biopsy, serving as a more efficient and less invasive means of detecting and subtyping this cancer.The most aggressive type of brain tumor, glioblastoma has a poor survival rate and limited treatment options. While it can currently be diagnosed through tumor biopsies, this method can be time consuming, invasive, and painful. There is a need to develop more effective options for detecting glio...
Continue reading

Understanding Glioblastoma Tumor-Associated Macrophages

One of the significant contributors to glioblastoma, a cancer of the brain and one of the most aggressive malignancies, tumor-associated macrophages have great potential as therapeutic targets; however, targeting these cells has not been effective, in part due to a limited understanding of the reasons behind their behavior. Researchers seeking to better understand this behavior have now discovered that tumor-associated macrophages are composed of two cell types: brain-resident microglia and bone...
Continue reading

CRISPR-Cas9 Technology Used to Understand Glioblastoma

The most common type of primary malignant brain tumor in adults, glioblastoma is also one of the deadliest cancers, with a median survival rate of 10 to 14 months. Until recently, understanding of glioblastoma growth and survival was limited. Now, scientists report that "reverse engineering" glioblastoma stem cells gene by gene using CRISPR-Cas9 unveiled multiple therapeutic targets to combat treatment resistance, including the SOX transcription factor family."We think that, in one big experimen...
Continue reading

Glioblastoma: New First-Line Treatment Regimen Provides Hope

​A phase 3 clinical trial has shown that a regimen consisting of lomustine and temozolomide in combination with radiotherapy can improve survival for patients with previously untreated glioblastoma with MGMT promoter methylation.Glioblastoma, the most common form of primary brain tumor, is highly aggressive and extremely deadly, with a five-year survival rate of only 5.6%. Standard treatment is radiotherapy followed by chemotherapy with temozolomide, an alkylating agent (a drug that interferes w...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.